What Are Cognitive Research Peptides?
Cognitive research peptides are synthetic compounds studied in preclinical and in vitro models for their neuromodulatory properties. Semax, Selank, and Dihexa represent three structurally distinct compound classes: an ACTH-derived fragment analog, a tuftsin-derived immunomodulatory peptide, and an angiotensin IV analog, respectively. Each compound is examined in published literature for effects on neurotrophin expression, receptor modulation, and synaptogenic signaling. These peptides function as pharmacological tools for interrogating discrete molecular pathways in the central nervous system — the kind of mechanistically precise probes that performance research labs require for characterizing neuromodulatory circuits.
Research interest in each compound stems from its selectivity for neurotrophic or inhibitory receptor systems, making them tractable in cell culture and animal model systems. Published work spans neuroprotection, anxiety-related behavior in rodent models, and synaptic plasticity. All three compounds are evaluated for research purposes only. Prove It Performance supplies research-grade preparations of each compound intended exclusively for laboratory and preclinical investigation.
How Does Semax Modulate BDNF and Cognitive Research Models?
Semax is a synthetic heptapeptide derived from adrenocorticotropic hormone fragment ACTH(4-7), extended at the C-terminus with a Pro-Gly-Pro sequence. Full sequence: Met-Glu-His-Phe-Pro-Gly-Pro. Published research has characterized Semax's capacity to upregulate brain-derived neurotrophic factor (BDNF) expression in neuronal cell cultures and rodent brain tissue models. Ashmarin et al. investigated Semax-induced BDNF elevation and downstream TrkB receptor activation in neuronal preparations [PMID: 16445185]. Medvedeva et al. examined gene expression profiles following Semax exposure in brain tissue models, identifying transcriptional changes across multiple neurotrophic pathways [PMID: 18841466]. The peptide's ACTH(4-7) core is thought to interact with melanocortin receptors, with secondary BDNF induction proposed downstream. These findings position Semax as a research tool for studying neurotrophin regulation in neuroprotection and cognitive function models.
For performance research labs, Semax's BDNF-upregulating profile and relatively small molecular footprint make it a tractable probe for studies requiring controlled neurotrophin pathway manipulation without direct TrkB agonism. All research applications use Semax for preclinical purposes only.
What Is the Anxiolytic Mechanism of Selank in Research?
Selank is a synthetic heptapeptide analog of the endogenous immunomodulatory tetrapeptide tuftsin, extended with Gly-Pro-Lys at the C-terminus. Amino acid sequence: Thr-Lys-Pro-Arg-Pro-Gly-Pro, with molecular formula C₄₆H₇₃N₁₃O₁₃ and molecular weight 1046.2 g/mol. Published research characterizes Selank as an allosteric modulator of GABA-A receptors in neuronal preparations. Kozlovskaya et al. described Selank's effects on GABA-A receptor subunit composition and chloride channel conductance in cell culture models [PMID: 22786332]. Kozlovsky et al. investigated Selank's influence on enkephalin system activity and neurotransmitter expression profiles in brain tissue preparations, identifying interactions with opioid receptor pathways [PMID: 22968004]. Uchakina et al. examined Selank's immunomodulatory properties, including modulation of interleukin expression in immune cell cultures [PMID: 20717095]. In animal models, Selank has demonstrated anxiolytic-like behavioral outcomes in elevated plus maze and open field paradigms.
Performance research labs studying the intersection of immunomodulation and GABAergic signaling will find Selank's dual-profile — GABA-A allosteric modulation plus tuftsin-derived immune effects — mechanistically distinct from classical GABAergic tools. All applications are for preclinical research only.
How Does Dihexa Activate HGF/c-Met Signaling Pathways?
Dihexa (also designated PNB-0408) is a synthetic hexapeptide analog of angiotensin IV developed as a potent agonist of the hepatocyte growth factor (HGF)/c-Met receptor complex. Published research by McCoy et al. demonstrated that Dihexa binds HGF with high affinity and transactivates c-Met signaling cascades in hippocampal preparations, producing synaptogenic effects in neuronal cultures [PMID: 23090578]. Bhatt et al. investigated synaptogenic properties in rodent models, observing increases in synaptic density markers in hippocampal tissue [PMID: 23548006]. HGF/c-Met signaling activates downstream PI3K/Akt and MAPK/ERK cascades associated with neuronal survival and synaptic remodeling. The angiotensin IV scaffold provides structural basis for Dihexa's high potency relative to endogenous HGF in receptor activation assays. Wright et al. established foundational angiotensin IV binding site characterization and its role in cognitive function models in rodents [PMID: 20888304]. Published findings identify Dihexa as a research probe for studying synaptogenesis and c-Met-dependent neuroprotection.
For performance research applications examining growth factor-mediated synaptic remodeling, Dihexa's potent and selective HGF/c-Met agonism makes it a distinct tool from neurotrophic receptor agonists like NGF or BDNF pathway tools. All applications are for preclinical research only.
Comparison Table
| Compound | Origin | Mechanism | Receptor Target | Molecular Weight | Primary Research Application | Key PMIDs |
|---|---|---|---|---|---|---|
| Semax | ACTH(4-7) analog | BDNF upregulation | TrkB (indirect) | 813 Da | Neuroprotection, cognitive studies | 16445185, 18841466 |
| Selank | Tuftsin analog | GABA-A modulation, enkephalin | GABA-A, opioid receptors | 1046 Da | Anxiolytic research, stress response | 22786332, 22968004, 20717095 |
| Dihexa | Angiotensin IV analog | HGF/c-Met agonism | c-Met | 811 Da | Synaptogenesis, cognitive research | 23090578, 23548006 |
What Does Published Research Show About Each Compound?
Published literature on Semax centers on BDNF elevation and neuroprotective gene expression. Ashmarin et al. documented BDNF induction and TrkB activation in neuronal cultures [PMID: 16445185]; Medvedeva et al. identified broad transcriptional changes in neurotrophic factor networks [PMID: 18841466]. For Selank, Kozlovskaya et al. established GABA-A receptor allosteric modulation as a primary mechanism [PMID: 22786332], with Kozlovsky et al. reporting enkephalin system activity effects [PMID: 22968004]. Dihexa research led by McCoy et al. and Bhatt et al. demonstrates potent HGF/c-Met transactivation and synaptogenic outcomes in hippocampal models [PMID: 23090578] [PMID: 23548006]. Across all three compounds, published findings derive from cell culture and rodent preclinical models. Prove It Performance provides each compound strictly for laboratory investigation.
Frequently Asked Questions
What distinguishes Semax from other ACTH-derived peptides in research?
Semax is distinguished by its specific ACTH(4-7) core sequence — Met-Glu-His-Phe — with a C-terminal Pro-Gly-Pro extension that enhances metabolic stability. Published research documents secondary BDNF induction and TrkB-dependent neurotrophic signaling as properties not consistently reported for other ACTH fragment analogs such as ACTH(1-24) or alpha-MSH [PMID: 16445185]. Medvedeva et al. showed that Semax modulates broader neuroplasticity gene networks beyond simple adrenocortical axis effects [PMID: 18841466]. For performance research labs, this differentiated neurotrophin profile — BDNF upregulation without direct receptor agonism — makes Semax mechanistically distinct from compounds that activate TrkB directly. All characterization is from preclinical research; Semax is supplied by Prove It Performance for research purposes only.
How is Selank's mechanism of action different from synthetic benzodiazepines in research models?
Selank and benzodiazepines both engage GABA-A receptors, but their binding sites and functional consequences differ in published research models. Classical benzodiazepines bind at the alpha/gamma subunit interface, producing canonical positive allosteric modulation. Selank's GABA-A interaction, characterized by Kozlovskaya et al., involves distinct subunit selectivity differing from the benzodiazepine binding profile [PMID: 22786332]. Additionally, Selank engages enkephalin system pathways — an interaction not associated with benzodiazepines [PMID: 22968004] — and carries tuftsin-derived immunomodulatory properties including effects on interleukin expression [PMID: 20717095]. For performance research designs requiring GABA-A modulation without full benzodiazepine pharmacology, Selank's distinct mechanistic fingerprint offers a differentiated experimental tool. Selank is available from Prove It Performance for research purposes only.
What is the significance of HGF/c-Met signaling in Dihexa research?
HGF/c-Met is a receptor tyrosine kinase pathway that regulates neuronal survival, synaptic plasticity, and axonal growth. Dihexa's research significance is its capacity to act as a potent HGF mimetic that transactivates c-Met independently of endogenous HGF ligand. McCoy et al. demonstrated picomolar-affinity HGF binding and downstream c-Met phosphorylation in hippocampal tissue [PMID: 23090578]. Activated c-Met drives PI3K/Akt and MAPK/ERK cascades associated with neuronal survival signaling and dendritic spine remodeling. Bhatt et al. reported increased synaptic density markers following Dihexa treatment in hippocampal rodent preparations [PMID: 23548006]. The HGF/c-Met axis is also implicated in neuroprotection following ischemic injury in preclinical models. For performance research labs investigating synaptogenic compounds, Dihexa's potency at this specific receptor system makes it a high-value pharmacological probe. All uses are for preclinical research only.
How do researchers measure BDNF changes in Semax studies?
Published Semax research employs ELISA-based protein quantification for BDNF levels in conditioned cell culture media and tissue homogenates. Quantitative PCR measures BDNF mRNA transcripts in neuronal preparations. Immunohistochemistry with anti-BDNF antibodies enables spatial localization in specific brain regions. Western blotting confirms mature BDNF protein versus precursor proBDNF levels. TrkB phosphorylation assays — phospho-TrkB ELISA and co-immunoprecipitation — confirm downstream receptor activation as characterized by Ashmarin et al. [PMID: 16445185]. Medvedeva et al. applied expression arrays to capture broader transcriptomic responses [PMID: 18841466]. All measurement approaches are applied in preclinical or in vitro contexts. Compound purity verification via HPLC before experimental use is required for reproducible results.
What research models are used to study Selank's anxiolytic properties?
Published Selank research primarily uses rodent behavioral paradigms including elevated plus maze (time in open vs. closed arms), open field test (locomotor activity and center-zone exploration), and stress-induced hyperthermia models. Kozlovskaya et al. and Kozlovsky et al. employed neurochemical endpoints including GABA-A receptor binding assays and enkephalin quantification to establish mechanistic correlates [PMID: 22786332] [PMID: 22968004]. Uchakina et al. used immune cell culture systems to characterize the immunomodulatory dimension of Selank activity [PMID: 20717095]. In vitro models complement behavioral work by enabling direct receptor binding measurements. Prove It Performance supplies Selank for use in these preclinical research contexts only — not for human or veterinary use.
All compounds listed are for research purposes only. Prove It Performance provides research-grade peptides intended for laboratory and preclinical research. Not for human or veterinary use.